 CAMBRIDGE, Mass., Aug. 09, 2021 GLOBE NEWSWIRE -- Trillium Therapeutics Inc. NASDAQTSX: TRIL, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first TP53-mutated acute myeloid leukemia AML patient with TTI-622 SIRPα-IgG4 Fc, an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine. 